Key Highlights

  • Rivian (NASDAQ:RIVN) rose about 4% to 5% after hours on October 29, 2026 after a third-quarter loss of USD 0.48 per share, narrower than consensus. Revenue was USD 2.155 billion, up 38%, and delivery guidance rose at the low end to 67,000 to 70,000 vehicles.
  • Eli Lilly (NYSE:LLY) jumped 6.7% to USD 1,374.21 on October 29, 2026 after raising 2026 revenue guidance to USD 91 billion to 92 billion. Third-quarter revenue was USD 24.4 billion against USD 22.6 billion expected, and adjusted Earnings were USD 7.48 per share.
  • Insmed (NASDAQ:INSM) rose 16% on October 29, 2026 after beating revenue expectations and raising full-year guidance, according to one account. No revenue, earnings or guidance figures were available, so the size of the raise is unknown.
  • Crocs (NASDAQ:CROX) soared about 25% on October 29, 2026 to its highest level in more than two years. HeyDude revenue rose 6.1% to USD 170 million, and the company raised its 2026 guidance for the third time.

Rivian (NASDAQ:RIVN): Narrower loss and delivery guide

Rivian (NASDAQ:RIVN) reported third-quarter results after the close on October 29, 2026. The loss was USD 0.48 per share, revenue was USD 2.155 billion, an increase of 38% from a year earlier, and the company delivered 19,248 vehicles. Management raised the low end of its full-year delivery guidance, which is now 67,000 to 70,000 vehicles, and lifted its adjusted EBITDA guide by USD 100 million at the midpoint. The shares rose about 4% to 5% after hours. The results are confirmed in two published accounts, but the consensus loss differs between them at USD 0.61 and USD 0.64, so the beat is labelled as narrower than expected, not as a precise figure. Delivery guidance is a range, and raising its low end narrows the range upward, which signals more confidence in the weakest case. Adjusted EBITDA measures operating profit before interest, taxes, depreciation, amortization and some other items, and a higher guide suggests the Business is losing money more slowly on that measure. A company can still post a loss per share while the trend improves, which is the pattern Rivian (NASDAQ:RIVN) showed. Growth of 38% in revenue against the prior year is large, but it comes from a smaller base, so investors will want to see whether deliveries keep rising.

Eli Lilly (NYSE:LLY): Beat with a raised revenue guide

Eli Lilly (NYSE:LLY) reported third-quarter results on October 29, 2026. Revenue of USD 24.4 billion beat the USD 22.6 billion consensus by about USD 1.8 billion, which is simple arithmetic on two published numbers and a gap of roughly 8%, and adjusted earnings of USD 7.48 per share beat an estimate of about USD 6.3. Management raised 2026 revenue guidance to USD 91 billion to 92 billion. The shares closed up 6.7% at USD 1,374.21. Intraday gains of 4.4% to 6.7% appeared in different accounts depending on the timestamp, but the closing figure is 6.7%, and three published accounts confirm the results and the guidance. The company release remains the primary check on every figure, and the Earnings Per Share guidance was lowered in the same release. The earnings outlook moved the other way. Adjusted earnings guidance was trimmed to USD 35 to 36 per share because acquired Research and Development charges of USD 4.57 per share are being counted. The charge is a one-time cost of buying future products, so the trimmed guide does not mean the current business is earning less.

Insmed (NASDAQ:INSM): Raised guidance, no figures

Insmed (NASDAQ:INSM) rose 16% on October 29, 2026 after beating revenue expectations and raising guidance. On the same day Norwegian Cruise Line rose 13% after a stronger third quarter and a higher 2026 EPS guide. These are the only confirmed facts: the revenue, EPS and guidance numbers were not in the published accounts, so this article cannot say how large either beat or raise was. Each direction was confirmed in a single account, which is a thinner standard than the two-account verification used for other names. Insmed is a biopharmaceutical company, and Norwegian Cruise Line is a cruise operator, so the only link between them is the direction of their guidance. A single day of strong trading does not make either stock a trend. Guidance is management's forecast for future results, and raising it tells investors that the business is tracking ahead of plan. A raise matters more than a beat alone because it resets expectations for coming quarters, and analysts revise models accordingly. For a commercial-stage biotech such as Insmed, growth in product sales drives the revenue line, while for a cruise operator, ticket pricing and onboard spending drive results.

Crocs (NASDAQ:CROX): Third raise and a HeyDude rebound

Crocs (NASDAQ:CROX) reported third-quarter results on October 29, 2026, and the stock soared about 25% to its highest level in more than two years. Three published accounts confirm the move and the main drivers. HeyDude, the company's second brand, grew revenue by 6.1% to USD 170 million, which is the first increase in six quarters. Management also raised its 2026 outlook for the third time this year. The consensus estimates, the new guidance ranges and the figures for the main Crocs Brand were not retrieved, so none is stated here. A one-day gain of about 25% is large for a consumer company and is why the shares drew attention. A brand that returns to growth after six quarters of declines changes how investors judge the business. HeyDude is the company's second brand, and six quarters without growth had kept attention on it. A rise of 6.1% is modest in size, and it comes from a small base, yet the direction matters because it suggests the brand may have stopped losing share.

Where Things Stand

The answer is that each company paired a better quarter with a better forecast, and investors paid for the second part. Rivian (NASDAQ:RIVN) narrowed its loss and lifted delivery guidance. Eli Lilly (NYSE:LLY) beat on revenue and earnings and raised revenue guidance. Insmed (NASDAQ:INSM) raised guidance, though the figures are missing. Crocs (NASDAQ:CROX) raised its outlook for a third time. Gaps remain: Insmed (NASDAQ:INSM) and Crocs lack guidance ranges, and Rivian's consensus loss differs between accounts. The next catalysts are the October 30 open and the next reports. This is not Investment advice.